Janssen has announced results from its Phase 3b exploratory trial evaluating the efficacy of Xarelto (rivaroxaban) as an alternative to vitamin K antagonists (VKAs) for treating and reducing the risk of blood clots in non-valvular atrial fibrillation (NVAF) in patients undergoing elective cardioversion.
Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.
In a recent case study in Case Reports - Drug Safety, miscommunication between pharmacists leads to unintentional duplicate anticoagulation therapy and elevated INR in a patient with a history of pulmonary embolism (PE).
Oral anticoagulation with rivaroxaban for stroke prevention in atrial fibrillation (AF) patients resulted in low rates of bleeding and stroke, researchers presented at the European Society of Cardiology Congress 2015.
Janssen Research & Development announced that the FDA has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) for Xarelto (rivaroxaban) seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
Janssen Research & Development announced that it has submitted supplemental New Drug Applications (sNDAs) to the FDA seeking approval for the use of Xarelto (rivaroxaban) to treat patients with deep vein thrombosis (DVT) or pulmonary embolism (PE) and prevention of recurrent venous thromboembolism (VTE).
Xarelto, a Factor Xa inhibitor, is currently indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Compared with warfarin, apixaban was correlated with reduced risk of major bleeding and intracranial bleeding (adjusted hazard ratios, 0.66 and 0.4, respectively) and dabigatran was correlated with reduced risk of intracranial bleeding (adjusted hazard ratio, 0.45) among patients with atrial fibrillation.
